Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CNTA Centessa Pharmaceuticals plc
- Stocks
- Healthcare
- NASDAQ: CNTA
Price (delayed)
$12.51
Market cap
$1.67B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.88
Enterprise value
$1.68B
Highlights
The revenue has surged by 119% year-on-year
The gross profit has soared by 119% YoY
CNTA's equity has soared by 80% YoY but it is down by 3.8% QoQ
The net income has plunged by 62% YoY but it has grown by 5% from the previous quarter
The debt is up by 37% year-on-year
Key stats
What are the main financial stats of CNTA
Market
Valuations
Earnings
Shares outstanding
133.62M
Market cap
$1.67B
Enterprise value
$1.68B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.31
Price to sales (P/S)
110.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
112.25
Revenue
$15M
Gross profit
$15M
Operating income
-$194.21M
Net income
-$223.85M
EBIT
-$209.65M
EBITDA
-$208.73M
Free cash flow
-$162.05M
Per share
Balance sheet
Liquidity
EPS
-$1.88
EPS diluted
-$1.88
Free cash flow per share
-$1.22
Book value per share
$2.9
Revenue per share
$0.11
TBVPS
$3.97
Total assets
$527.85M
Total liabilities
$141.6M
Debt
$117.37M
Equity
$386.25M
Working capital
$323.52M
Debt to equity
0.3
Current ratio
14.37
Quick ratio
11.76
Net debt/EBITDA
-0.06
Margins
Efficiency
Dividend
EBITDA margin
-1,391.5%
Gross margin
100%
Net margin
-1,492.3%
Operating margin
-1,294.7%
Return on assets
-42.4%
Return on equity
-56.9%
Return on invested capital
-61.2%
Return on capital employed
-41.6%
Return on sales
-1,397.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CNTA stock price
How has the Centessa Pharmaceuticals stock price performed over time
Intraday
-0.64%
1 week
1.71%
1 month
5.75%
1 year
39.78%
YTD
-25.31%
QTD
-13%
Financial performance
How have Centessa Pharmaceuticals's revenue and profit performed over time
Revenue
$15M
Gross profit
$15M
Operating income
-$194.21M
Net income
-$223.85M
Gross margin
100%
Net margin
-1,492.3%
The revenue has surged by 119% year-on-year
The gross profit has soared by 119% YoY
The net income has plunged by 62% YoY but it has grown by 5% from the previous quarter
Centessa Pharmaceuticals's operating margin has increased by 44% YoY
Price vs fundamentals
How does CNTA's price correlate with its fundamentals
Growth
What is Centessa Pharmaceuticals's growth rate over time
Valuation
What is Centessa Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.31
P/S
110.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
112.25
The company's EPS fell by 33% YoY but it rose by 9% QoQ
CNTA's equity has soared by 80% YoY but it is down by 3.8% QoQ
CNTA's price to book (P/B) is 54% higher than its 5-year quarterly average of 2.8 but 2% lower than its last 4 quarters average of 4.4
The revenue has surged by 119% year-on-year
Efficiency
How efficient is Centessa Pharmaceuticals business performance
The company's return on sales rose by 38% YoY
Centessa Pharmaceuticals's return on invested capital has increased by 23% QoQ but it has decreased by 9% YoY
The company's return on equity rose by 15% QoQ
Centessa Pharmaceuticals's return on assets has increased by 14% QoQ but it has decreased by 12% YoY
Dividends
What is CNTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CNTA.
Financial health
How did Centessa Pharmaceuticals financials performed over time
CNTA's total assets has surged by 61% year-on-year but it is down by 8% since the previous quarter
CNTA's current ratio has surged by 55% since the previous quarter and by 39% year-on-year
The debt is 70% smaller than the equity
CNTA's equity has soared by 80% YoY but it is down by 3.8% QoQ
The debt is up by 37% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.